Its quarterly performance is likely to have benefited from this development. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The light blue area represents the range of Wall Street analysts' earnings estimates for … GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom. Zacks Equity Research Analysts expect GW Pharmaceuticals PLC- to post earnings of ($0.58) per share for the quarter. LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Chairman, Start Your Risk-Free Trial Subscription Here, Pfizer (NYSE:PFE) Stock: A Strong Option for Dividend Investors. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. In the last-reported quarter, the company delivered a negative earnings surprise of 72.7%. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Cabot Brown, Douglas B Snyder, Geoffrey W Dr Guy, Justin D Gover, Scott M Giacobello, and Volker Knappertz.
Their forecasts range from $128.00 to $275.00. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. If you wish to go to ZacksTrade, click OK. GW Pharmaceuticals PLC- (NASDAQ:GWPH) will be releasing its earnings data after the market closes on Thursday, August 6th.
Learn more. Learn everything you need to know about successful options trading with this three-part video course. View GW Pharmaceuticals PLC-'s Short Interest.
The business's revenue was up 68.4% compared to the same quarter last year. All these should get reflected in the company’s second-quarter results. View our full suite of financial calendars and market data tables, all for free. A "Second Wave" that involves the stock market, election, as well as 5 popular tech "darlings" that could crash hard. Currently, 17.6% of the company's shares are sold short. Jeff Brown, a member of the US Chamber of Digital Commerce issues a special warning to Mr. Trump.
All these developments are anticipated to have aided the company’s second-quarter international revenues. Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave.
This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) posted its quarterly earnings results on Thursday, August, 6th. View insider buying and selling activity for GW Pharmaceuticals PLC-.
To see all exchange delays and terms of use please see disclaimer. Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more! 80.52% of the stock of GW Pharmaceuticals PLC- is held by institutions. NYSE and AMEX data is at least 20 minutes delayed. All rights reserved. ), GW Pharmaceuticals PLC- has received 537 “underperform” votes.
Looking for new stock ideas? Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Top institutional shareholders include Laidlaw Wealth Management LLC (11.80%), Federated Hermes Inc. (2.65%), Victory Capital Management Inc. (1.85%), M&G Investment Management Ltd. (1.72%), Point72 Asset Management L.P. (1.66%) and Bank of New York Mellon Corp (1.20%). Get the latest GW Pharma ADR earnings report, revenues as well as upcoming GWPH earnings dates, historical financial reports, news, analysis & more. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. During the same period last year, the firm posted $0.21 EPS.
High institutional ownership can be a signal of strong market trust in this company.